Phreesia Reports Strong Q4/FY26 Results, Lowers FY27 Revenue Guidance Amid Pharma Spending Uncertainty
Summary
Phreesia reported a return to GAAP profitability and strong cash flow for fiscal year 2026, but significantly lowered its revenue outlook for fiscal year 2027 due to reduced visibility into pharmaceutical manufacturer spending.
Key Events
-
Q4 & FY2026 Financial Performance
Reported Q4 revenue of $127.1 million (up 16% Y/Y) and full-year revenue of $480.6 million (up 14% Y/Y). The company achieved positive GAAP net income of $2.3 million for FY2026, a significant improvement from a $58.5 million net loss in FY2025.
-
FY2027 Revenue Guidance Cut
Lowered fiscal year 2027 revenue outlook to $510-$520 million, down from a previous range of $545-$559 million, citing reduced visibility into pharmaceutical manufacturer spending.
-
Adjusted EBITDA Outlook Maintained
Despite the revenue reduction, the company maintained its fiscal year 2027 Adjusted EBITDA outlook of $125-$135 million, indicating expected operational efficiencies, including through AI adoption.
-
Debt Refinancing Completed
Subsequent to year-end, the company refinanced its $90 million Bridge Loan with a new 5-year, $275 million senior secured revolving credit facility, enhancing liquidity and financial flexibility. This follows the 8-K filed on March 16, 2026.
Analysis
Phreesia's latest 8-K reveals a mixed financial picture. While the company achieved positive GAAP net income and substantial free cash flow for fiscal year 2026, demonstrating a significant operational turnaround, its forward guidance for fiscal year 2027 revenue has been notably reduced. This cut, attributed to shorter visibility and lower spending commitments from pharmaceutical manufacturers, signals potential headwinds for growth. The company's ability to maintain its Adjusted EBITDA outlook despite the revenue reduction suggests strong cost management and efficiency gains, partly driven by AI adoption. However, the market is likely to focus on the deceleration in revenue growth, especially as the stock is currently trading below its 52-week low. Investors will be watching for further clarity on pharmaceutical spending trends and the impact on Phreesia's network solutions segment.
At the time of this filing, PHR was trading at $8.91 on NYSE in the Trade & Services sector, with a market capitalization of approximately $687.9M. The 52-week trading range was $10.75 to $32.76. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.